JP2024525580A - Ｉｒａｋ４タンパク質の分解をターゲティングするための化合物 - Google Patents
Ｉｒａｋ４タンパク質の分解をターゲティングするための化合物 Download PDFInfo
- Publication number
- JP2024525580A JP2024525580A JP2024500312A JP2024500312A JP2024525580A JP 2024525580 A JP2024525580 A JP 2024525580A JP 2024500312 A JP2024500312 A JP 2024500312A JP 2024500312 A JP2024500312 A JP 2024500312A JP 2024525580 A JP2024525580 A JP 2024525580A
- Authority
- JP
- Japan
- Prior art keywords
- pharma
- optionally substituted
- acceptable salt
- alkyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163219167P | 2021-07-07 | 2021-07-07 | |
| US63/219,167 | 2021-07-07 | ||
| US202263354020P | 2022-06-21 | 2022-06-21 | |
| US63/354,020 | 2022-06-21 | ||
| PCT/US2022/036409 WO2023283372A1 (en) | 2021-07-07 | 2022-07-07 | Compounds for targeting degradation of irak4 proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024525580A true JP2024525580A (ja) | 2024-07-12 |
| JP2024525580A5 JP2024525580A5 (cg-RX-API-DMAC10.html) | 2025-07-11 |
Family
ID=82748787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024500312A Pending JP2024525580A (ja) | 2021-07-07 | 2022-07-07 | Ｉｒａｋ４タンパク質の分解をターゲティングするための化合物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20250018046A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4366834A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024525580A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023283372A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12022500002A1 (en) | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| US12558427B2 (en) | 2019-07-17 | 2026-02-24 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| WO2021119159A1 (en) | 2019-12-10 | 2021-06-17 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CA3161878A1 (en) | 2019-12-17 | 2021-06-24 | Matthew M. Weiss | Irak degraders and uses thereof |
| WO2024020522A1 (en) * | 2022-07-22 | 2024-01-25 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of irak-4 |
| CN117777126A (zh) * | 2022-09-29 | 2024-03-29 | 武汉人福创新药物研发中心有限公司 | 作为irak4降解剂的咪唑并吡啶类化合物及其用途 |
| EP4638447A1 (en) * | 2022-12-21 | 2025-10-29 | Dark Blue Therapeutics Ltd | Imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives as mllt1 and mllt3 inhibitors |
| EP4389747A1 (en) * | 2022-12-21 | 2024-06-26 | Dark Blue Therapeutics Ltd | Imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives as mllt1 and mllt3 inhibitors |
| EP4428134A1 (en) * | 2023-03-10 | 2024-09-11 | Dark Blue Therapeutics Ltd | Protac degraders of mllt1 and/or mllt3 |
| CN116251488B (zh) * | 2023-03-13 | 2024-05-24 | 石河子大学 | 一种用于分离二氧化碳的含氨基功能材料及其制备方法和应用 |
| WO2024208256A1 (zh) * | 2023-04-03 | 2024-10-10 | 上海汇伦医药股份有限公司 | 靶向蛋白降解化合物及其制备方法和应用 |
| KR20260005340A (ko) * | 2023-05-30 | 2026-01-09 | 상하이 후이룬 파마슈티컬 컴퍼니 리미티드 | 트리시클릭 화합물, 이의 제조 방법 및 적용 |
| CN122206684A (zh) | 2023-06-30 | 2026-06-12 | 默克专利有限公司 | 用于kras蛋白降解的异双功能化合物 |
| JP2026524477A (ja) | 2023-06-30 | 2026-07-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｋｒａｓの分解のためのヘテロ二官能性化合物 |
| EP4763839A1 (en) * | 2023-08-15 | 2026-06-24 | Pamplona Therapeutics (Shenzhen) Co., Ltd. | Compound targeting irak protein inhibition or degradation and use thereof |
| CN118955497B (zh) * | 2023-08-21 | 2025-10-31 | 泰诺瑞(天津)生物科技有限责任公司 | 一种咪唑并[1,2-a]吡啶类IRAK4降解剂及其应用 |
| CN122270449A (zh) * | 2023-12-13 | 2026-06-23 | 百济神州(苏州)生物科技有限公司 | 通过将irak4抑制剂与e3连接酶配体缀合来降解irak4以及使用方法 |
| WO2025130871A1 (zh) * | 2023-12-20 | 2025-06-26 | 爱科诺生物医药(香港)有限公司 | 具有irak4和flt3蛋白双重降解活性的化合物，包含其的药物组合物，及其应用 |
| WO2026136866A1 (en) | 2024-12-20 | 2026-06-25 | Prelude Therapeutics Incorporated | Kat6 targeting compounds |
| WO2026139448A1 (en) | 2024-12-23 | 2026-07-02 | Merck Patent Gmbh | Heterobifunctional compounds for the degradation of kras protein |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017500326A (ja) * | 2013-12-19 | 2017-01-05 | バイエル・ファルマ・アクティエンゲゼルシャフト | 新規なインダゾールカルボキサミド、その調製法、これらを含む医薬製剤および医薬品を製造するためのその使用 |
| WO2019099926A1 (en) * | 2017-11-17 | 2019-05-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
| WO2020150626A1 (en) * | 2019-01-18 | 2020-07-23 | Biogen Ma Inc. | Imidazo[1,2-a]pyridinyl derivatives as irak4 inhibitors |
| WO2020264499A1 (en) * | 2019-06-28 | 2020-12-30 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2021011868A1 (en) * | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2021083949A1 (en) * | 2019-10-29 | 2021-05-06 | F. Hoffmann-La Roche Ag | Bifunctional compounds for the treatment of cancer |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| EP4649963A3 (en) | 2014-04-14 | 2026-05-13 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| MX375925B (es) * | 2014-06-25 | 2025-03-07 | Hoffmann La Roche | Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal. |
| JO3705B1 (ar) * | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| JP6815318B2 (ja) | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| JP6817962B2 (ja) | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| AU2016232705C1 (en) | 2015-03-18 | 2021-06-17 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| CA2988414C (en) | 2015-06-04 | 2023-09-26 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| EP3319944A4 (en) | 2015-07-10 | 2019-04-24 | Arvinas, Inc. | MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS |
| CA2988436A1 (en) | 2015-07-13 | 2017-01-19 | Arvinas, Inc. | Alanine-based modulators of proteolysis and associated methods of use |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| GB201516243D0 (en) | 2015-09-14 | 2015-10-28 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US20170281784A1 (en) | 2016-04-05 | 2017-10-05 | Arvinas, Inc. | Protein-protein interaction inducing technology |
| AU2017246452C1 (en) | 2016-04-06 | 2021-06-03 | The Regents Of The University Of Michigan | MDM2 protein degraders |
| AU2017250076B2 (en) | 2016-04-12 | 2021-07-22 | The Regents Of The University Of Michigan | Bet protein degraders |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| CN121974842A (zh) | 2016-05-10 | 2026-05-05 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| EP3512842B1 (en) | 2016-09-15 | 2024-01-17 | Arvinas, Inc. | Indole derivatives as estrogen receptor degraders |
| SI3526202T1 (sl) | 2016-10-11 | 2025-04-30 | Arvinas Operations, Inc. | Spojine in postopki za ciljno razgradnjo androgenskih receptorjev |
| MX2019005007A (es) | 2016-11-01 | 2019-07-18 | Arvinas Inc | Protac dirigidos a la proteína tau y métodos asociados de uso. |
| IL266842B (en) | 2016-12-01 | 2022-09-01 | Arvinas Operations Inc | History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists |
| US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| IL325835A (en) | 2016-12-23 | 2026-03-01 | Univ Yale | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
| CN110753693A (zh) | 2016-12-23 | 2020-02-04 | 阿尔维纳斯运营股份有限公司 | Egfr蛋白水解靶向嵌合分子和相关使用方法 |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| IL300417A (en) | 2017-01-26 | 2023-04-01 | Arvinas Operations Inc | Bifunctional benzothiophene compounds, preparations containing them and their use in therapy |
| IL319363A (en) | 2017-01-31 | 2025-05-01 | Arvinas Operations Inc | Cervalon ligands and bifunctional compounds containing them |
| EP3634960A1 (en) | 2017-06-09 | 2020-04-15 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| EP4717317A3 (en) | 2017-06-20 | 2026-06-03 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| WO2019023553A1 (en) | 2017-07-28 | 2019-01-31 | Arvinas, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF THE ANDROGEN RECEPTOR |
| EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION |
| AU2019249849C1 (en) | 2018-04-01 | 2022-09-29 | Arvinas Operations, Inc. | BRM targeting compounds and associated methods of use |
| CA3095912A1 (en) | 2018-04-13 | 2019-10-17 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| WO2019204354A1 (en) | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Spirocyclic compounds |
| CN110835338A (zh) * | 2018-08-17 | 2020-02-25 | 浙江海正药业股份有限公司 | 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途 |
| EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN BREAKDOWN |
| ES2995214T3 (en) | 2019-03-06 | 2025-02-07 | C4 Therapeutics Inc | Heterocyclic compounds for medical treatment |
| KR102947433B1 (ko) | 2019-04-12 | 2026-04-06 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
| WO2020259626A1 (zh) * | 2019-06-26 | 2020-12-30 | 南京明德新药研发有限公司 | 作为irak4抑制剂的咪唑并吡啶类化合物 |
-
2022
- 2022-07-07 WO PCT/US2022/036409 patent/WO2023283372A1/en not_active Ceased
- 2022-07-07 EP EP22748646.1A patent/EP4366834A1/en active Pending
- 2022-07-07 US US18/576,933 patent/US20250018046A1/en active Pending
- 2022-07-07 JP JP2024500312A patent/JP2024525580A/ja active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017500326A (ja) * | 2013-12-19 | 2017-01-05 | バイエル・ファルマ・アクティエンゲゼルシャフト | 新規なインダゾールカルボキサミド、その調製法、これらを含む医薬製剤および医薬品を製造するためのその使用 |
| WO2019099926A1 (en) * | 2017-11-17 | 2019-05-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
| WO2020150626A1 (en) * | 2019-01-18 | 2020-07-23 | Biogen Ma Inc. | Imidazo[1,2-a]pyridinyl derivatives as irak4 inhibitors |
| WO2020264499A1 (en) * | 2019-06-28 | 2020-12-30 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2021011868A1 (en) * | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2021083949A1 (en) * | 2019-10-29 | 2021-05-06 | F. Hoffmann-La Roche Ag | Bifunctional compounds for the treatment of cancer |
Non-Patent Citations (1)
| Title |
|---|
| ACS MED. CHEM. LETT., vol. 10, JPN6026014191, 2019, pages 1251 - 1252, ISSN: 0005916741 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4366834A1 (en) | 2024-05-15 |
| WO2023283372A1 (en) | 2023-01-12 |
| US20250018046A1 (en) | 2025-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4366834A1 (en) | Compounds for targeting degradation of irak4 proteins | |
| US20240343733A1 (en) | Compounds for targeting degradation of irak4 proteins | |
| JP7576552B2 (ja) | イミダゾ［１，２－ａ］ピリジニル誘導体及び疾患の処置におけるその使用 | |
| KR101962495B1 (ko) | C-kit 키나제 억제제로서의 화합물 및 조성물 | |
| WO2022266258A1 (en) | Compounds and methods for the targeted degradation of irak-4 | |
| KR101959590B1 (ko) | c-KIT 키나제 억제제로서의 화합물 및 조성물 | |
| JP6259824B2 (ja) | Ｔｎｆ活性の調節物質としてのイミダゾピラジン誘導体 | |
| JP2024519496A (ja) | ブルトンのチロシンキナーゼの分解を標的化するための化合物 | |
| JP7257387B2 (ja) | スピロ環化合物並びにその作製及び使用方法 | |
| KR20190040319A (ko) | N-(피리딘-2-일)피리딘-술폰아미드 유도체 및 질환의 치료에서 이들의 용도 | |
| WO2015086527A1 (en) | Fused tricyclic imidazole derivatives as modulators of tnf activity | |
| CA3082156A1 (en) | Heterocyclic compound as a protein kinase inhibitor | |
| MX2012013127A (es) | Compuestos heteroariloxiheterociclilo como inhibidores pde10. | |
| KR20220042132A (ko) | 2h-이미다졸 유도체 및 질환 치료에서 그의 용도 | |
| WO2024020522A1 (en) | Compounds and methods for the targeted degradation of irak-4 | |
| AU2017327539A1 (en) | Heteroaryl carboxamide compounds as inhibitors of RIPK2 | |
| CN117642157A (zh) | 具有((3-硝基苯基)磺酰基)乙酰胺作为bcl-2抑制剂的化合物 | |
| TW202045501A (zh) | 雙環醚o-糖蛋白-2-乙醯胺基-2-去氧-3-d-哌喃葡萄糖苷酶抑制劑 | |
| US20230183237A1 (en) | Competitive and noncompetitive inhibitors of the muscarinic acetylcholine receptor m5 | |
| KR20260022448A (ko) | 디히드로피리미딘-2,4(1h,3h)-디온을 함유하는 폴리시클릭 유도체 및 이의 약학적 조성물, 이의 제조 방법 및 이의 용도 | |
| TW202506660A (zh) | Mrgprx2拮抗劑及其使用方法 | |
| CN117940414A (zh) | 用于靶向irak4蛋白降解的化合物 | |
| CN117957225A (zh) | 用于靶向irak4蛋白的降解的化合物 | |
| EA050233B1 (ru) | Соединения для направленной деградации белков irak4 | |
| CA3037141C (en) | Heteroaryl carboxamide compounds as inhibitors of ripk2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250703 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250703 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20260319 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260410 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260710 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20260727 |